Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "metastatic castration-resistant prostate cancer" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-4 z 4
    Tytuł:
    Apalutamide as a new option for postponing metastatic disease in hormone -resistant patients with biochemical recurrence in prostate cancer
    Autorzy:
    Dąbek, Bartosz
    Powiązania:
    https://bibliotekanauki.pl/articles/22676825.pdf
    Data publikacji:
    2023-04-04
    Wydawca:
    Medical Education
    Tematy:
    non-metastatic castration-resistant prostate cancer
    apalutamide
    Opis:
    Treatment of non-metastatic castration-resistant prostate cancer is a radically new option for cancer patients. Novel anti-hormonal therapy not only improves metastasis free survival but overall survival times and positively impacts quality of life. This case shows how apalutamide lowered tPSA level and postponed metastatic disease.
    Źródło:
    OncoReview; 2023, 13, 1; 24-26
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Prostate cancer in clinical practice. First experiences with apalutamide within the context of therapeutic program B.56
    Autorzy:
    Trzebiński, Krzysztof
    Powiązania:
    https://bibliotekanauki.pl/articles/22676841.pdf
    Data publikacji:
    2023-04-01
    Wydawca:
    Medical Education
    Tematy:
    non-metastatic castration-resistant prostate cancer
    apalutamide
    androgen receptor inhibitor
    Opis:
    The article contains a case report of patient diagnosed with castration-resistant non-metastatic prostate cancer, treated with a novel androgen receptor inhibitor – apalutamide.
    Źródło:
    OncoReview; 2023, 13, 1; 27-30
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Survival outcome and prognostic factors in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with abiraterone acetate – real-world experience in Vietnam
    Autorzy:
    Do, Tu Anh
    Nguyen, Thai Hoa Thi
    Nguyen, Hau Xuan
    Nguyen, Loi Dinh
    Nguyen, Chu Van
    Powiązania:
    https://bibliotekanauki.pl/articles/40555372.pdf
    Data publikacji:
    2024-06-30
    Wydawca:
    Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
    Tematy:
    abiraterone acetate
    metastatic castration-resistant prostate cancer
    overall survival
    real-world evidence
    Opis:
    Introduction and aim. In real life, metastatic castration-resistant prostate cancer patients (mCRPC) had more complex clinical presentation than patients in the COU-AA-302 trial. This study primarily aimed to describe the overall survival of chemotherapy-naive mCRPC treated with abiraterone acetate plus prednisone (AAP). Other relevant outcomes and baseline characteristics of these patients were also evaluated. Material and methods. This retrospective, observational study collected data from chemotherapy-naive mCRPC patients treated with AAP in Vietnam. Kaplan-Meier curves were used to estimate time to treatment failure (TTF), and overall survival (OS). The impact of baseline characteristics on OS was explored using univariate and multivariate Cox proportional hazard models. Results. Data from 65 eligible patients were analyzed. The rate of PSA response was 73.8%, median PSA PFS was 10.5 months (95% CI: 7.4–13.6), median TTF was 15 months (95% CI: 11.1–18.9), and median OS was 24.9 months (95% CI: 18.9–30.9). Shorter OS was significantly associated with a higher Gleason score (≥8), shorter time from ADT start to mCRPC (<12 months), visceral metastases, and <50% PSA decline (p<0.05). Conclusion. Abiraterone acetate plus prednisone is well tolerated and effective for chemotherapy-naive mCRPC patients in clinical practice. Moreover, Gleason score, visceral metastasis, time from ADT start to mCRPC, and PSA response are the independent indicators for predicting the OS of mCRPC patients in both univariate and multivariate analyses.
    Źródło:
    European Journal of Clinical and Experimental Medicine; 2024, 22, 2; 262-269
    2544-2406
    2544-1361
    Pojawia się w:
    European Journal of Clinical and Experimental Medicine
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Apalutamid for treatment of nonmetastatic castration-resistant prostate cancer - case study
    Autorzy:
    Sikora-Kupis, Bożena
    Powiązania:
    https://bibliotekanauki.pl/articles/22676707.pdf
    Data publikacji:
    2023-03-31
    Wydawca:
    Medical Education
    Tematy:
    non-metastatic castration-resistant prostate cancer
    nmCRPC
    androgen receptor targeted agents
    ARTA
    apalutamide
    darolutamide
    enzalutamide
    Opis:
    A special form of prostate cancer is non-metastatic castration-resistant prostate cancer. Patients with this form have rising prostate-specific antigen and castrate testosterone levels, with no radiological findings of metastatic disease on computed tomography and bone scan. The phase III trials demonstrated apalutamide, darolutamide or enzalutamide to be associated with a significantly longer median metastasis-free survival. The featured description presents one case of man with non-metastatic castration-resistant prostate cancer who was treated with apalutamide.
    Źródło:
    OncoReview; 2023, 13, 1; 6-8
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-4 z 4

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies